Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, open-label, single-center, nonrandomized, 2-cohort study was conducted in healthy subjects: a single centre study

Trial Profile

A phase 1, open-label, single-center, nonrandomized, 2-cohort study was conducted in healthy subjects: a single centre study

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2018

At a glance

  • Drugs Acalabrutinib (Primary) ; Acalabrutinib (Primary)
  • Indications B-cell lymphoma; B-cell prolymphocytic leukaemia; Bladder cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Glioblastoma; Head and neck cancer; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Rheumatoid arthritis; Waldenstrom's macroglobulinaemia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Dec 2018 New trial record
    • 15 Nov 2018 Results assesssing the pharmacokinetics of Acalabrutinib in healthy volunteers, published in the Drug Metabolism and Disposition.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top